X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (60) 60
humans (52) 52
hematology (38) 38
female (30) 30
mutation (28) 28
leukemia (27) 27
male (26) 26
pathology (26) 26
aged (25) 25
oncology (25) 25
adult (24) 24
middle aged (23) 23
aged, 80 and over (16) 16
patients (15) 15
lymphomas (14) 14
myelodysplastic syndromes (14) 14
abridged index medicus (12) 12
analysis (12) 12
follow-up studies (12) 12
prognosis (12) 12
survival (12) 12
biopsy (11) 11
cancer (11) 11
lymphoma (11) 11
bone marrow (10) 10
immunohistochemistry (10) 10
myelodysplastic syndromes - genetics (10) 10
p53 protein (10) 10
article (9) 9
mutations (9) 9
acute myeloid-leukemia (8) 8
expression (8) 8
genetic aspects (8) 8
myelodysplastic syndromes - pathology (8) 8
neoplasms (8) 8
next-generation sequencing (8) 8
tp53 (8) 8
treatment outcome (8) 8
tumor proteins (8) 8
bone marrow - pathology (7) 7
cll (7) 7
diagnosis (7) 7
immunophenotyping (7) 7
in situ hybridization, fluorescence (7) 7
kaplan-meier estimate (7) 7
karyotyping (7) 7
patient outcomes (7) 7
transformation (7) 7
chronic lymphocytic leukemia (6) 6
cytogenetics (6) 6
flow cytometry (6) 6
gene mutations (6) 6
genes (6) 6
hemic and lymphatic diseases (6) 6
high-throughput nucleotide sequencing - methods (6) 6
ibrutinib (6) 6
myeloproliferative disorders - genetics (6) 6
polymerase chain reaction (6) 6
stem cells (6) 6
therapy (6) 6
transplantation (6) 6
young adult (6) 6
abnormalities (5) 5
acute myeloid leukemia (5) 5
b-cell lymphoma (5) 5
biomarkers, tumor - genetics (5) 5
care and treatment (5) 5
chemotherapy (5) 5
chromosomes (5) 5
chronic lymphatic leukemia (5) 5
chronic lymphocytic-leukemia (5) 5
classification (5) 5
clonal evolution (5) 5
gene (5) 5
health aspects (5) 5
imatinib (5) 5
impact (5) 5
leukemia, lymphocytic, chronic, b-cell - genetics (5) 5
mantle cell lymphoma (5) 5
medical research (5) 5
minimal residual disease (5) 5
myelodysplastic syndrome (5) 5
myeloid leukemia (5) 5
myeloproliferative disorders - pathology (5) 5
neoplasms - genetics (5) 5
non-hodgkin's lymphomas (5) 5
research (5) 5
risk factors (5) 5
t cells (5) 5
tumors (5) 5
adolescent (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
cell biology (4) 4
cell survival (4) 4
chronic myelogenous leukemia (4) 4
clonal hematopoiesis (4) 4
cyclophosphamide - administration & dosage (4) 4
dasatinib (4) 4
deoxyribonucleic acid--dna (4) 4
diagnosis, differential (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Modern Pathology, ISSN 0893-3952, 08/2015, Volume 28, Issue 8, pp. 1014 - 1022
Journal Article
Modern Pathology, ISSN 0893-3952, 08/2016, Volume 29, Issue 8, p. 939
Journal Article
Modern Pathology, ISSN 0893-3952, 08/2016, Volume 29, Issue 8, pp. 939 - 939
Journal Article
MODERN PATHOLOGY, ISSN 0893-3952, 08/2016, Volume 29, Issue 8, pp. 939 - 939
Journal Article
FASEB Journal, ISSN 0892-6638, 03/2006, Volume 20, Issue 3, pp. 530 - 532
Journal Article
British Journal of Haematology, ISSN 0007-1048, 12/2018, Volume 183, Issue 5, pp. 831 - 835
Table SII. The JAK2 V617F AS-qPCR cutoff of >0.05% at day +180 following allogeneic hematopoietic stem cell transplantation reliably distinguished JAK2 V617F... 
myelofibrosis | minimal residual disease | allogeneic hematopoietic stem cell transplantation | MUTATION | MYELOPROLIFERATIVE NEOPLASMS | ASSAYS | HEMATOLOGY | Transplantation | Hematopoietic stem cells | Stem cells | Janus kinase 2 | Myelofibrosis | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 11/2017, Volume 123, Issue 22, pp. 4391 - 4402
In the current study, myeloid immunophenotype, prior treatment with tyrosine kinase inhibitors (TKIs), older age, higher lactate dehydrogenase level, low... 
tyrosine kinase inhibitors (TKI) | dasatinib | nilotinib | imatinib | ponatinib | blast phase (BP) | bosutinib | chronic myeloid leukemia (CML) | CHRONIC MYELOGENOUS LEUKEMIA | CML | MANAGEMENT | ABNORMALITIES | SENSITIVITY | MECHANISMS | ONCOLOGY | CRISIS | MUTATIONS | Blast Crisis - drug therapy | Prognosis | Humans | Middle Aged | Risk Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Young Adult | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis | Protein Kinase Inhibitors - therapeutic use | Adolescent | Blast Crisis - mortality | Survival Analysis | Aged, 80 and over | Blast Crisis - diagnosis | Adult | Female | Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Cohort Studies | Protein-Tyrosine Kinases - antagonists & inhibitors | Cancer patients | Chemotherapy | Usage | Patient outcomes | Chronic myeloid leukemia | Health aspects | Cancer | Transformation | Dehydrogenases | Leukemia | Stem cell transplantation | Transplantation | Blast | Multivariate analysis | Parameter identification | Dehydrogenase | Historical account | Failure analysis | Chromosome 15 | Protein-tyrosine kinase | Age | Tyrosine | Phase transformations | Myeloid leukemia | Abnormalities | Lactate dehydrogenase | Regression analysis | Patients | Survival | L-Lactate dehydrogenase | Inhibitors | Medical prognosis | Stem cells | Lactic acid | Aberration | Platelets | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 03/2016, Volume 127, Issue 10, pp. 1269 - 1275
Journal Article
Cancer, ISSN 0008-543X, 10/2017, Volume 123, Issue 19, pp. 3717 - 3724
In the current study, tumor protein 53 ( TP53 ) mutations are found to be present in 15% of patients with newly diagnosed adult acute lymphoblastic leukemia.... 
tumor protein 53 | hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper‐CVAD) | TP53 | acute lymphoblastic leukemia (ALL) | next‐generation sequencing | hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) | next-generation sequencing | tumor protein 53 (TP53) | SURVIVAL | vincristine | RELAPSE | and dexamethasone (hyper-CVAD) | IMPACT | THERAPY | GENE | ONCOLOGY | FREQUENCY | hyperfractionated cyclophosphamide | doxorubicin | MINIMAL RESIDUAL DISEASE | DELETIONS | CORRELATE | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Humans | Middle Aged | Male | Mutation, Missense | Tumor Suppressor Protein p53 - genetics | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - drug therapy | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Genes, p53 | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Aged, 80 and over | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - genetics | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Treatment Outcome | Sequence Analysis, DNA | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - genetics | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Alleles | Aged | Mutation | Dexamethasone | Cell survival | Acute lymphatic leukemia | Leukemia | p53 Protein | Blood cells | Lymphatic leukemia | Survival | Patients | Doxorubicin | Vincristine | Philadelphia chromosome | Cyclophosphamide | Lymphocytes B | Monoclonal antibodies | Remission | Deoxyribonucleic acid--DNA | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2014, Volume 32, Issue 2, pp. 114 - 120
Journal Article
Journal Article